The Committee recommended that robust evidence is generated to demonstrate the impact of using the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care in England. The impact on excision rates, diagnostic accuracy, health‑related quality of life and associated NHS costs should be reported.
The Committee recommended the collection of data on the proportion of people with melanoma who are referred into secondary care under the 2‑week wait rule, the proportion of equivocal moles that are excised and the proportion that are monitored.
The Committee recommended the collection of data on the number of confirmatory diagnostic biopsies before definitive treatment, in people who have a clinical diagnosis of basal cell carcinoma. Data on the different modalities used to treat basal cell carcinoma should also be collected.
The Committee recommended the generation of robust evidence to demonstrate the clinical effectiveness of using the VivaScope 1500 and 3000 imaging systems to define margins of lentigo maligna and basal cell carcinoma compared with histological margins determined by Mohs surgery.
The Committee recommended the collection of data on the incidence of lentigo maligna diagnosed in England. Data on the different therapies used to treat lentigo maligna should also be collected.